Harry Penner

Harry H.
Penner was the founder of Nascent BioSciences Inc. (founded in 2001) where the title held was Chairman & Chief Executive Officer.
Mr. Penner was the founder of Marinus Pharmaceuticals, Inc. (founded in 2003) with the title of Director.
Mr. Penner was the founder of QCDx LLC (founded in 2017) holding the title of Chairman.
Mr. Penner was the founder of Melinta Subsidiary Corp.
(founded in 2000) with the title of Director from 2000 to 2009.
Mr. Penner is the founder of New Haven Pharmaceuticals, Inc. (founded in 2008) serving as Executive Chairman since 2012.
Mr. Penner is also the founder of Prevention Pharmaceuticals, Inc.,Affinimark Technologies, Inc.,RHEI Pharmaceuticals, Inc.,Virscio, Inc.,Omax Health, Inc...
Mr. Penner currently serves as Chairman & Chief Executive Officer at Nascent BioScience LLC since 2001.
Mr. Penner is Chairman at Celldex Therapeutics, Inc. starting in 2025.
Mr. Penner holds Director positions at MAKScientific LLC, CaroGen Corp., Neurovail, Inc., and Aria Neurosciences, Inc. Former positions include Vice Chairman, President & Chief Executive Officer at Neurogen Corp.
from 1999 to 2001.
Chairman at Celldex Therapeutics, Inc. (Old).
Chairman at Connecticut Technology Council.
Chairman at Connecticut Board of Governors for Higher Education.
Co-Chairman at Connecticut United for Research Excellence, Inc. Director at AVANT Immunotherapeutics, Inc. from 1997 to 2008.
Director at Genaissance Pharmaceuticals, Inc. Lead Director at Altus Pharmaceuticals, Inc. from 2006 to 2009.
Director at Ikonisys, Inc. Director at Connecticut Business & Industry Association.
Executive Vice President at Novo Nordisk A from 1988 to 1993.
President & EVP-North America at Novo Nordisk North America, Inc. from 1988 to 1993.
Education includes undergraduate studies at the University of Virginia, graduate studies at Fordham University, and graduate studies at New York University.